Girentuximab is used for the treatment of clear cell renal cell carcinoma (ccRCC) by targeting carbonic anhydrase IX (CA9), a glycoprotein widely expressed on the surface of ccRCC cells; it is also utilized as a radioimmunoconjugate in oncology applications.